Advertisement

Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction

  • Dimitrios Patoulias
    Correspondence
    Corresponding author at: Second Propedeutic Department of Internal Medicine, General Hospital “Hippokration”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece.
    Affiliations
    Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece
    Search for articles by this author
  • Christodoulos Papadopoulos
    Affiliations
    Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece
    Search for articles by this author
  • Michael Doumas
    Affiliations
    Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital “Hippokration”, Thessaloniki, Greece

    Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia, United States
    Search for articles by this author
Published:February 22, 2021DOI:https://doi.org/10.1016/j.ejim.2021.02.009
      We have read with great interest the meta-analysis performed by Qiu et al. [
      • Qiu M
      • Ding L-L
      • Zhan Z-L
      • Zhou H-R.
      Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?.
      ] published in the European Journal of Internal Medicine, assessing the cardio-renal efficacy of different sodium-glucose co-transporter 2 (SGLT-2) inhibitors across major co-morbidities, namely type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF). Unfortunately, the authors did not address surrogate endpoints with SGLT-2 inhibitors use in patients with two or three kinds of diseases since the patient-level data were not available, as they state in their article. Co-existence of main co-morbidities with HFrEF increases the risk for cardiovascular morbidity and mortality and all-cause mortality, underscoring the undoubted need for appropriate, targeted treatment options [
      • Seferović PM
      • Petrie MC
      • Filippatos GS
      • et al.
      Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
      ,
      • Shah KS
      • Xu H
      • Matsouaka RA
      • et al.
      Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Qiu M
        • Ding L-L
        • Zhan Z-L
        • Zhou H-R.
        Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?.
        Eur J Intern Med. 2021; https://doi.org/10.1016/j.ejim.2021.01.009
        • Seferović PM
        • Petrie MC
        • Filippatos GS
        • et al.
        Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
        Eur J Heart Fail. 2018; 20: 853-872
        • Shah KS
        • Xu H
        • Matsouaka RA
        • et al.
        Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.
        J Am Coll Cardiol. 2017; 70: 2476-2486
        • McMurray JJV
        • Solomon SD
        • Inzucchi SE
        • et al.
        Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Packer M
        • Anker SD
        • Butler J
        • et al.
        Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
        N Engl J Med. 2020; 383: 1413-1424
        • Petrie MC
        • Verma S
        • Docherty KF
        • et al.
        Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
        JAMA. 2020; 323: 1353-1368
        • Anker SD
        • Butler J
        • Filippatos G
        • et al.
        Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial [published online ahead of print, 2020 Nov 11].
        Circulation. 2020; (10.1161/CIRCULATIONAHA.120.051824)https://doi.org/10.1161/CIRCULATIONAHA.120.051824
        • Zannad F
        • Ferreira JP
        • Pocock SJ
        • et al.
        Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial [published online ahead of print, 2020 Oct 23].
        Circulation. 2020; (10.1161/CIRCULATIONAHA.120.051685)https://doi.org/10.1161/CIRCULATIONAHA.120.051685
        • Jhund PS
        • Solomon SD
        • Docherty KF
        • et al.
        Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF [published online ahead of print, 2020 Oct 12].
        Circulation. 2020; (10.1161/CIRCULATIONAHA.120.050391)https://doi.org/10.1161/CIRCULATIONAHA.120.050391
        • Deeks JJ
        • Higgins JPT
        • Altman DG.
        Chapter 9: Analyzing data and undertaking meta-analyses.
        in: Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0.eds. John Wiley & Sons Ltd, Chichester, England2011
      1. Review Manager (RevMan) [Computer program] Version [5.3] Copenhagen: The Nordic Cochrane Centre TCC; 2014.

        • Higgins JPT
        • Sterne JAC
        • Savović J
        • Page MJ
        • Hróbjartsson A
        • Boutron I
        • Reeves B
        • Eldridge S.
        A revised tool for assessing risk of bias in randomized trials.
        Cochrane Database Syst Rev. 2016; 10: 29-31
        • Zannad F
        • Ferreira JP
        • Pocock SJ
        • et al.
        SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
        Lancet. 2020; 396: 819-829